Yesterday I started my review of Abiomed and its unique strategic shift to focus on heart recovery. Despite being the first company with a patented and reimbursed artificial heart, Abiomed altered its focus five years ago. After speaking with its CEO, Mike Minogue, I see that he followed pattern 23: moving upstream.
To assist or replace? That was the question that Mike Minogue focused on during his first few weeks as the new chief executive officer of Abiomed (NASDAQ: ABMD), a technology company that created the first artificial heart. A student of Sun Tzu and Clausewitz, Mike learned strategy in the U.S. Army and then applied his knowledge to GE before becoming CEO of Abiomed five years ago.